Pfizer Rapped Over ADR Reporting

26 May 1996

- The US Food and Drug Administration has accused Pfizer of laxity in reporting serious side effects from some of its major products, including its best-selling calcium antagonist for hypertension, Procardia XL (nifedipine), and the antidepressant Zoloft (sertraline). Last year and in 1994, Pfizer reported side effects with its products between 77 and 514 days late, according to the agency, which adds that other violations dating back to 1983 have been uncovered.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight